Design of multi-target D-Ala-D-Ala ligase ligands
多靶点D-Ala-D-Ala连接酶配体的设计
基本信息
- 批准号:7979299
- 负责人:
- 金额:$ 24.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffinityAgonistAlanineAlanine RacemaseAnabolismAnti-Bacterial AgentsAntibioticsAntimycobacterial AgentsBindingBinding SitesBiochemical ProcessBiological AssayCell WallCellsCessation of lifeComputer SimulationCrude ExtractsCycloserineCytolysisD-Alanine-D-alanine ligaseDataDevelopmentDipeptidesDivalent CationsDrug DesignEffectivenessEnterococcusEnzymesEpidemicEscherichia coliEssential GenesExtreme drug resistant tuberculosisFundingGenus MycobacteriumGrowthHumanLateralLeadLigand BindingLigandsMulti-Drug ResistanceMutagenesisMycobacterium tuberculosisN-MethylaspartateNebraskaOsmotic PressureOutcomePeptidesPeptidoglycanPharmaceutical PreparationsPhosphotransferasesPhysiological ProcessesPopulationProcessProteinsProtocols documentationReactionReportingResistanceResolutionSalmonella typhimuriumScreening procedureSiteStaphylococcus aureusStructureTexasTherapeutic AgentsToxic effectTuberculosisUniversitiesValidationVertebral columnanalogantimicrobial drugassay developmentbactericidebasecrosslinkdesigndrug developmentenantiomerenzyme mechanisminorganic phosphatemicroorganismmycobacterialneurotransmissionnovelnovel therapeuticspathogenpublic health relevancereceptorresistant strainscaffoldstemtuberculosis treatment
项目摘要
DESCRIPTION (provided by applicant): Mycobacterium tuberculosis is a major epidemic today, causing 8 million new cases and 3 million deaths yearly world-wide. New anti-tubercular drugs that act through novel mechanisms are urgently needed for more efficacious treatments in combination with existing drugs and for treating multi-drug resistant strains that emerged in recent years. The bacterial cell wall contains peptidoglycan that provides resistance from external osmotic pressure. Targeting steps of peptidoglycan biosynthesis is an attractive mechanism for new antibacterial agents. An essential step is the synthesis of D-Alanyl-D-Alanine dipeptide (D-Ala-D-Ala) that is required for the formation of peptidoglycan and for cross-linking peptidoglycan strands. The enzyme catalyzing this process is D-Alanyl-D-Alanine ligase (DDl). DDl is an excellent target for new antibiotics since synthesis of D-Ala-D-Ala is an essential process for bacterial growth and furthermore there is no human equivalent to DDl. We have applied an in silico structure based approach to identify and assay DDl ATP and substrate site binding ligands using sets of compounds that have shown activity against M. tuberculosis TB H37Rv in HTS screening and kinase binding ligands that show structural similarities to DDl. We propose to refine and validate DDl binding prediction protocols in the first half of the proposed effort and utilize these to identify and assay compounds based on known scaffolds of valid anti-tubercular targets for activity against DDl.
PUBLIC HEALTH RELEVANCE: New anti-tubercular drugs that act through novel mechanisms are urgently needed for more efficacious treatments of tuberculosis and for treating multi-drug resistant strains that recently emerged. In this proposal we have apply an in silico structure based approach to identify and assay novel potent DDl binders and multi- TB target ligands.
描述(由申请人提供):结核分枝杆菌今天是一种主要流行病,每年造成800万例新病例和300万人死亡。迫切需要通过新的机制与现有药物结合使用新型机制,并治疗近年来出现的多药抗性菌株,因此迫切需要通过新型机制起作用的新的抗结核药物。细菌细胞壁含有肽聚糖,可提供外部渗透压的抗性。靶向肽聚糖生物合成的步骤是新型抗菌剂的有吸引力的机制。一个必不可少的步骤是合成D-丙选 - 丙氨酸二肽(D-Ala-d-Ala),这是形成肽聚糖和交联肽聚糖链所必需的。催化此过程的酶是D-丙氨酸 - 丙氨酸连接酶(DDL)。 DDL是新抗生素的绝佳靶标,因为D-ALA-D-ALA的合成是细菌生长的重要过程,而且没有人类等于DDL。我们使用基于硅结构的方法应用了基于硅结构的方法来识别和测定DDL ATP和底物位点结合配体,使用一组化合物在HTS筛选中显示了与结核分枝杆菌TB H37RV的活性,在HTS筛选和激酶结合配体中显示出与DDL的结构相似性。我们建议在拟议的努力的上半年中完善和验证DDL结合预测方案,并利用这些方案来识别和测定基于有效抗结核靶标的已知脚手架,用于针对DDL的活性。
公共卫生相关性:迫切需要通过新型机制起作用的新抗结核药物来对结核病进行更有效的治疗方法,并治疗最近出现的多药抗性菌株。在此提案中,我们采用了基于硅结构的方法来识别和测定新型有效的DDL粘合剂和多TB靶配体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Judith Varady Hobrath其他文献
Judith Varady Hobrath的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Judith Varady Hobrath', 18)}}的其他基金
Design of multi-target D-Ala-D-Ala ligase ligands
多靶点D-Ala-D-Ala连接酶配体的设计
- 批准号:
8098979 - 财政年份:2010
- 资助金额:
$ 24.94万 - 项目类别:
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
开发阿片受体模型以合理设计双功能配体
- 批准号:
7687911 - 财政年份:2008
- 资助金额:
$ 24.94万 - 项目类别:
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
开发阿片受体模型以合理设计双功能配体
- 批准号:
7512750 - 财政年份:2008
- 资助金额:
$ 24.94万 - 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Identification of allosteric molecules for DOR-KOR heteromer-mediated peripheral analgesia
DOR-KOR 异聚体介导的外周镇痛变构分子的鉴定
- 批准号:
10608439 - 财政年份:2023
- 资助金额:
$ 24.94万 - 项目类别:
CD98hc Brain Shuttles for Delivering Off-the-shelf Neuroprotective Antibodies in Alzheimer's Disease
CD98hc 脑穿梭机为阿尔茨海默病提供现成的神经保护抗体
- 批准号:
10566062 - 财政年份:2023
- 资助金额:
$ 24.94万 - 项目类别:
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment of methamphetamine use disorder
混合 NOP/mu 部分激动剂作为治疗甲基苯丙胺使用障碍的先导化合物的鉴定
- 批准号:
10577374 - 财政年份:2023
- 资助金额:
$ 24.94万 - 项目类别: